Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 152

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1A
Chunk 152
---
(a)(2) of the Securities Act of 1933, as
amended, as a transaction by an issuer not involving a public offering. The purchasers of securities in each of these transactions represented
their intention to acquire securities for investment only and not with a view to offer or sell, in connection with any distribution of
the securities, and appropriate legends were affixed to the share certificates and instruments issued in such transactions.

Purchases
of Equity Securities by the Registrant and Affiliated Purchasers

None.

Securities
Authorized for Issuance

The
following table sets forth securities authorized for issuance under any equity compensation plan approved by our stockholders as well
as any equity compensation plans not approved by our stockholders as of March 31, 2025.

    Equity Compensation Plan Information

    Plan category 
    Number of securities to be issued upon exercise of outstanding options, warrants, and rights  
    Weighted average exercise price of outstanding options, warrants, and rights  
    Number of Securities remaining available for future issuance under  equity compensation plans (excluding securities  reflect in table)

    Plans approved by shareholders(1) 
     
     1,140,933  
    $2.58  
    822,605

    Plans not approved by shareholders(2)  
     
     562,817  
    $2.00  
    —

  (1)
  PetVivo Holdings, Inc. Amended and Restated 2020 Equity Incentive
Plan.

  (2)
  Represents warrants granted to officers, directors, employees,
financial advisors, consultants, investors, and other service providers pursuant to individual contracts, investments, awards, or arrangements
for compensatory purposes.

Use
of proceeds from our initial public offering of common stock

On
August 13, 2021, we completed our Public Offering pursuant to which we issued and sold an aggregate of 2,500,000 units at the public
offering price of $4.50 per unit. Each unit consisted of one share of our common stock and one warrant to purchase one share of our common
stock at an exercise price of $5.625 per share. The shares of common stock and warrants were transferable separately immediately upon
issuance. At the closing of the Public Offering, the underwriter exercised its over-allotment option to purchase an additional 375,000
warrants for an aggregate purchase price of $3,850.

The